Article
Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.
The Journal of clinical endocrinology and metabolism - 1 May 2010
Regan Fiona M, Williams Rachel M, McDonald Anna, Umpleby A Margot, Acerini Carlo L, O'Rahilly Stephen, Hovorka Roman, Semple Robert K, Dunger David B
Abstract excerpt
OBJECTIVE: Diabetes in the context of severe insulin resistance (SIR) presents a major therapeutic challenge because conventional therapies including insulin and insulin sensitizers often fail to achieve adequate metabolic control. Adjunctive therapy with recombinant human IGF-I (rhIGF-I)/recombinant human IGF binding protein-3 (rhIGFBP-3) has been shown to improve insulin sensitivity in both type 1 and type 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.